HBM Partners With Bristol-Myers Squibb for Drug Discovery Collaboration

HBM Holdings Ltd has entered a drug discovery collaboration with Bristol-Myers Squibb. The collaboration aims to develop new treatments for various diseases, including immuno-oncology and immunology diseases. HBM Holdings is an investment holding company with a portfolio of products, including HBM9161 for immune thrombocytopenia, Graves' ophthalmopathy, myasthenia gravis, and neuromyelitis optica spectrum disorder. The company also researches and develops immuno-oncology assets and owns the Harbour Mice Platform for generating fully human monoclonal antibodies.